double-blind, placebo-controlled, multicenter, parallel-group study of one-year
duration followed by 2 years of open-label treatment to determine the safety and
efficacy of orally administered 2.5 mg or 5.0 mg risedronate in children > 4
to < 16 years old with osteogenesis imperfecta
In collaboration with Wright State University and
Miami Valley Hospital of Dayton, OH, we studied OI diagnosed
children, 4 to 16 years old, during a three-year osteogenesis
imperfecta study. The medicine to be tested is risedronate and belongs to a
group of medicines called bisphosphonates. This medicine has been shown to
increase bone density in adults, while maintaining bone structure and quality,
and therefore makes bones less likely to break.
for the study is closed.